Searched for
CIPLA STRATEGY
Q4 earnings review: Motilal Oswal highlights broad-based beat on estimates, lists 6 sectors that exceeded expectationsMotilal Oswal said Q4 FY26 earnings surpassed expectations, with aggregate profits rising 16% year-on-year against its 8% estimate. Strong ...- Cipla is aiming for 40-50 global product filings in three years, says MD Achin GuptaCipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant...
- Innovation, biosimilars, complex generics to drive Cipla's growth: Achin Gupta, MD & Group CEOAs Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to...
- Geopolitical stability will decide market’s next move: Sandip SabharwalIndian equity markets are holding above 24,000, buoyed by improving sentiment and steady earnings, though geopolitical tensions remain a co...
- Rahul Shah bullish on pharma, sees Sun Pharma and Aurobindo as key large-cap playsIndian equity markets show a mixed but improving consumption trend, with selective FMCG and premium retail outperforming. Page Industries i...
- Is India Inc's CSR truly driving systemic change or just shifting funds?Corporate India is entering a new phase of CSR. Spending is expected to cross ₹1.2 lakh crore by 2035. Companies are shifting towards syste...
- Q4 earnings, crude oil, FII action among 8 factors to steer D-Street this weekIndian stock markets are set for a busy week. Key events like Q4 earnings announcements for many companies will influence trading. Foreign ...
- Parag Parikh Flexi Cap Fund increase stake ITC, TCS, HDFC Bank and 14 other stocks in AprilParag Parikh Flexi Cap Fund boosted its holdings in ITC, TCS, and HDFC Bank during April. The fund also increased its stake in fourteen oth...
- LIC’s $2 billion contrarian bet: 10 stocks the DII giant bought while the market bledLife Insurance Corporation of India invested nearly $2 billion in 10 stocks during the March quarter's market fall. LIC bought shares in co...
- Cipla's vice-chairman MK Hamied resigns citing age and health, his son Kamil to join the boardCipla's vice-chairman MK Hamied has resigned from the board due to age and health concerns, effective October 29, 2024. His son Kamil Hamie...
- We see faster and significant growth in US: Samina Vaziralli, executive vice-chairperson, CiplaAs executive vice-chairperson of Cipla, Samina Vaziralli represents the third generation from the promoter’s family involved in its managem...
- What we had done for India, we are now doing for US: Umang Vohra, MD, CiplaIn an interview with Suman Layak, Vohra explains his strategy of taking Cipla products to global markets.
- Cipla divests animal health business in South Africa, sub-Saharan AfricaThe deal comes with a potential revision linked to FY17 performance along with customary adjustment (within the price band of 250 mn Rand a...
- Cipla names Samina Vaziralli as Executive Vice-ChairmanVaziralli, daughter of MK Hamied -- the company's non-executive VC - has been a part of the core leadership team since joining the Mumbai-b...
- Cipla acquires marketing rights of derma player Percos IndiaCipla has acquired the exclusive rights to market skin care products of the country’s leading derma and cosmeceutical player Percos India.
- Cipla completes buyout of Cipla Medpro for Rs 2,707 croreCipla on Tuesday said it has completed the buyout process of South African pharma firm Cipla Medpro for an aggregate consideration of Rs 2,...
- Cipla will prioritise African markets for growth: CEO Subhanu SaxenaCipla will prioritise emerging markets across the African continent in its growth plans, the company's CEO Subhanu Saxena has said.
- Brokers’ Call: Espirito puts a buy on CiplaEspirito Santo Securities has given a ‘Buy’ rating on Cipla with a fair value of Rs 440.
- Cipla, Ranbaxy to outperform pharma space: KR Choksey SecOne will have to look at Cipla and Ranbaxy as the potential candidate for outperformance in the pharma space in coming year.
- Safe & steady strategy gives Cipla lead over RanbaxySome years ago, investors were hooked to Ranbaxy Labs’ growth story and the many earnings triggers that lay ahead.
Load More
